ASACOL 800 TABLET (DELAYED-RELEASE)

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

MESALAZINE

Sẵn có từ:

ALLERGAN INC

Mã ATC:

A07EC02

INN (Tên quốc tế):

MESALAZINE

Liều dùng:

800MG

Dạng dược phẩm:

TABLET (DELAYED-RELEASE)

Thành phần:

MESALAZINE 800MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

180

Loại thuốc theo toa:

Prescription

Khu trị liệu:

ANTI-INFLAMMATORY AGENTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0116808010; AHFS:

Tình trạng ủy quyền:

CANCELLED POST MARKET

Ngày ủy quyền:

2021-01-27

Đặc tính sản phẩm

_ _
_Page 1 of 26_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ASACOL
TM 800
Mesalamine Tablets (Delayed-Release) *
Tablets, 800 mg, Oral
Mfr. Std.
Lower Gastrointestinal Anti-inflammatory
Allergan Inc.
85 Enterprise Blvd., Suite 500
Markham, Ontario
L6G 0B5
www.allergan.ca
Date of Initial Approval:
April 26, 2005
Date of Revision:
March 18, 2021
Submission Control No: 245722
* also referred to as 5-aminosalicylic acid (5-ASA)
_ _
_ _
_Page 2 of 26_
RECENT MAJOR LABEL CHANGES
WARNINGS AND PRECAUTIONS, Renal
04/2020
WARNINGS AND PRECAUTIONS, Acute Intolerance Syndrome
03/2021
WARNINGS AND PRECAUTIONS, 7.1.2 Breast-feeding
03/2021
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 4
1
INDICATIONS
.................................................................................................................
4
1.1
Pediatrics
...............................................................................................................
4
1.2
Geriatrics
...............................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
...........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
....................................................... 5
4.3
Administration
.............................................................